Sight Sciences announced two key hires: Sam Park, joining as Chief Operating Officer, and Jeremy Hayden, who joins as General Counsel and Chief Compliance Officer.
“We are excited to be able to add leaders with the outstanding track records of Sam and Jeremy as Sight Sciences continues to grow,” Paul Badawi, Chief Executive Officer of Sight Sciences, said in a company news release. “During their careers, both have proven the ability to scale organizational capabilities and processes to support the dynamic needs of high-growth medical device businesses. The ability to add these esteemed professionals to an already world-class team speaks to our mission-driven company culture, the substantial opportunity to make an impact on the fields of glaucoma and dry eye, and the real potential for our technologies to transform today’s standard of care for millions of patients suffering from these prevalent eye diseases.”
Sam Park will be responsible for scaling the company’s manufacturing, operations, and research and development capabilities to support the company’s growth initiatives. He brings 25 years of medical device experience, including executive-level leadership roles at SurgRx (acquired by Johnson & Johnson’s Ethicon Endo-Surgery division), Novacept (acquired by Cytyc), Arthrocare (acquired by Smith+Nephew), Origin Medsystems (acquired by Eli Lily and Company), and CardioGenesis (acquired by CryoLife).
Jeremy Hayden has over 20 years of experience providing legal counsel to life science businesses, including serving as the in-house counsel for several leading health care companies. Most recently, Hayden served as General Counsel and Chief Compliance Officer for Endologix, Inc., a medical device company developing devices for aortic disorders. Prior to this, Hayden served as General Counsel at publicly traded Cytori Therapeutics, Inc., a biotechnology company advancing cell therapies, and as a senior legal team member of Volcano prior to its acquisition by Royal Philips.